Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Retatrutide

Retatrutide is an investigational agonist at GIP, GLP-1, and glucagon receptors. Randomized phase 2 trials reported metabolic effects and frequent gastrointestinal adverse events. A peer-reviewed phase 3 type 2 diabetes trial was published in 2026; topline announcements should be distinguished from peer-reviewed trial reports.

Aliases reviewed
RETA, LY3437943
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
SubstantialSeveral randomized trials (phase 2 and phase 3) of an investigational medicine.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Clinical development studies weight, glycemic, liver, and cardiometabolic outcomes.

Identity

Retatrutide is an investigational agonist at GIP, GLP-1, and glucagon receptors.

Biological mechanism or research interest

Clinical development studies weight, glycemic, liver, and cardiometabolic outcomes.

Verified approved human uses

The reviewed phase 2 and phase 3 trial records describe investigational retatrutide; they do not establish marketing approval or validate catalogue material.

Investigational human evidence

Randomized phase 2 trials reported metabolic effects and frequent gastrointestinal adverse events. A peer-reviewed phase 3 type 2 diabetes trial was published in 2026; topline announcements should be distinguished from peer-reviewed trial reports.

Calling retatrutide superior, a best seller, or clinically effective outside the studied populations and development program is unsupported.

Human versus animal or cell evidence

Receptor rationale and animal pharmacology do not replace confirmatory clinical trials.

Limitations and known risks

Long-term benefit-risk, rare events, applicability beyond studied populations, and formulation quality for unverified catalogue material remain unresolved.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.